1620837-70-8
Chemical Structure
Bi-Mc-VC-PAB-MMAE
- CAS No.: 1620837-70-8
- Formula:C71H104N12O18
- Molecular Weight:1413.66
IUPAC Name: 4-((S)-2-((S)-2-(2-((1,3-bis(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)propan-2-yl)oxy)acetamido)-3-methylbutanamido)-5-ureidopentanamido)benzyl ((S)-1-(((S)-1-(((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl)(methyl)amino)-3-methyl-1-oxobutan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)(methyl)carbamate
InChIKey: LGNKBBQOTXBJFY-USLNFXPWSA-N
SMILES: O[C@@H](C1=CC=CC=C1)[C@@H](C)NC([C@H](C)[C@H]([C@@]2([H])N(CCC2)C(C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)C(OCC3=CC=C(C=C3)NC([C@H](CCCNC(N)=O)NC([C@H](C(C)C)NC(COC(CN4C(C=CC4=O)=O)CN5C(C=CC5=O)=O)=O)=O)=O)=O)=O)=O)=O)OC)=O
Biological Activity: Bi-Mc-VC-PAB-MMAE consists ADCs linker (Bi-Mc-Val-Cit-PAB) and potent tubulin inhibitor (MMAE, HY-15162). Bi-Mc-VC-PAB-MMAE is a drug-linker conjugate for ADC.
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Bi-Mc-VC-PAB-MMAE | 98.43% | Bi-Mc-VC-PAB-MMAE consists ADCs linker (Bi-Mc-Val-Cit-PAB) and potent tubulin inhibitor (MMAE, HY-15162). Bi-Mc-VC-PAB-MMAE is a drug-linker conjugate for ADC. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
MAL-di-EG-Val-Cit-PAB-MMAE | 99.92% | MAL-di-EG-Val-Cit-PAB-MMAE consists the ADCs linker (MAL-di-EG-Val-Cit-PAB) and potent tubulin inhibitor (MMAE). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Mal-Phe-C4-VC-PAB-MMAE | 99.54% | Mal-Phe-C4-VC-PAB-MMAE is a drug-linker conjugate for ADC composed of MMAE conjugated to the Mal-Phe-C4-VC-PAB linker. Mal-Phe-C4-VC-PAB-MMAE can be used to synthesize ROR1-targeting antibody-drug conjugates (ADCs) for research on ROR1-expressing cancers. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Mal-Cyclobutane-1,1-dicarboxamide-Cit-PAB-MMAE | Mal-Cyclobutane-1,1-dicarboxamide-Cit-PAB-MMAE (Compound 31) is a Drug-Linker Conjugates for ADC. Mal-Cyclobutane-1,1-dicarboxamide-Cit-PAB-MMAE is composed of MMAE (HY-15162) and Mal-Cyclobutane-1,1-dicarboxamide-Cit-PAB carbonic acid (HY-171663) . | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
OH-Glu-Val-Cit-PAB-MMAE | 99.03% | OH-Glu-Val-Cit-PAB-MMAE consists a cleavable ADC linker (OH-Glu-Val-Cit-PAB) and a potent tubulin inhibitor (MMAE). SuO-Glu-Val-Cit-PAB-MMAE can be used in the synthesis of antibody-drug conjugates (ADCs). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(Aminooxy)acetamide-Val-Cit-PAB-MMAE | 96.87% | (Aminooxy)acetamide-Val-Cit-PAB-MMAE (MMAE 5) is an intermediate used in the synthetic preparation of drug-linker conjugates for ADC. (Aminooxy)acetamide-Val-Cit-PAB-MMAE is conjugated to polyamide via oxime bond formation to form MMAE polyamide conjugate. Then MMAE polyamide conjugate can be conjugated to Trastuzumab, to make ADC. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
MC-EVCit-PAB-MMAE | 99.67% | MC-EVCit-PAB-MMAE (Linker-Payload 11) is a drug-linker conjugates for ADC. MC-EVCit-PAB-MMAE contains the ADCs linker (MC-EVCit-PAB) and a potent tubulin polymerization inhibitor MMAE (HY-15162). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
VcMMAE | 100.7% | VcMMAE (mc-vc-PAB-MMAE) is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
DBM-C5-VC-PAB-MMAE | 99.45% | DBM-C5-VC-PAB-MMAE (Compound 3a) is a Drug-Linker conjugate for ADC. DBM-C5-VC-PAB-MMAE is composed of a linker C5-VC-PAB with a maleimide group DBM and an ADC toxin MMAE (HY-15162). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Mal-Val-Lys-PAB-MMAE | Mal-Val-Lys-PAB-MMAE is a drug-linker conjugate for ADC. Mal-Val-Lys-PAB-MMAE consists of a Tubulin inhibitor (MMAE) (HY-15162) and a linker (Mal-Val-Lys-PAB). Mal-Val-Lys-PAB-MMAE can be used for synthesis of ADCs. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
mDPR-Val-Cit-PAB-MMAE TFA | 98.36% | mDPR-Val-Cit-PAB-MMAE TFA is a drug-linker conjugate for ADC (Drug-Linker Conjugates for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and an ADC linker (peptide Val-Cit- PAB) composition. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
